Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference
22 9월 2022 - 9:00PM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical
company focused on transforming medicines to transform lives,
announced today that members of management will participate in a
fireside chat at the Ladenburg Thalmann Healthcare Conference on
Thursday, September 29 at 12:30 p.m. E.T.
A live webcast of the fireside chat, as well as an archived
recording, will be available on Avadel’s Investor Relations
website, investors.avadel.com, for 90 days following the
conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical
company focused on transforming medicines to transform lives. Our
approach includes applying innovative solutions to the development
of medications that address the challenges patients face with
current treatment options. Our current lead drug candidate,
LUMRYZ™, is an investigational formulation of sodium oxybate
leveraging our proprietary drug delivery technology and designed to
be taken once at bedtime for the treatment of cataplexy or
excessive daytime sleepiness in adults with narcolepsy. For more
information, please visit www.avadel.com.
Investor Contact:Courtney TurianoStern Investor
Relations, Inc.Courtney.Turiano@sternir.com (212) 698-8687
Media Contact:Gabriella GreigReal
Chemistryggreig@realchemistry.com(203) 249-2688
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024